B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
MPLT
MapLight TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-28
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.3
Score
AI commentary
Primary-source sentiment improved materially after the positive ZEPHYR BID result, but the QD miss, prior IRIS failure, reported sharp selloff, absent social context, and unavailable analyst revisions support a cautious monitoring stance rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-07-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-22catalystIRIS primary-endpoint miss limits ASD optionalityHigh impact
The IRIS Phase 2 study missed its primary endpoint; a promising adolescent irritability subgroup supports further FDA discussion but remains exploratory [#PR-EARNINGS-2026-06-22].
2026-07-27eventZEPHYR Phase 2 success in schizophreniaHigh impact
The 210/3 mg BID arm met the primary PANSS endpoint with effect size 0.37 and showed positive cognition and secondary-endpoint results; the QD arm did not reach statistical significance [#SEC-8K-2026-07-27].
2026-10-26eventFDA interaction and confirmatory-trial planningHigh impact
MapLight plans an End-of-Phase 2 FDA meeting and an additional registrational trial for ML-007C-MA, but the regulatory path and replication remain uncertain [#SEC-8K-2026-07-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-28 • Updated nightlySource: Internal modelMethodology